Han Rachel, Hashmi Atif A, Wen Hannah Y, Murray Melissa, Kuba M Gabriela, Seidman Andrew D, Morrow Monica, Brogi Edi
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Medicine, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Histopathology. 2025 Aug;87(2):235-245. doi: 10.1111/his.15461. Epub 2025 Apr 29.
Microinvasive lobular carcinoma (MILC) is a rare form of minimally invasive carcinoma with incomplete pathological and clinical characterisation. We sought to identify the clinical and pathological features of MILC diagnosed at our institution between 2009 and 2023.
Patient demographic, pathological and clinical data were collected. Patients with a prior or synchronous history of invasive carcinoma were excluded. The study cohort included 30 female patients with a median age of 53 years. The most common imaging target was microcalcifications (63%). MILC was diagnosed on biopsy alone in three cases (10%), excision alone in 22 cases (73%) and on both biopsy and excision in five cases (17%). Most MILCs were unifocal (57%). MILCs were associated with classic lobular carcinoma in-situ (LCIS) in 90% of cases, florid LCIS in 27% and pleomorphic LCIS in 17%. None of 21 patients (70%) who underwent sentinel lymph node biopsy had lymph node involvement. Biomarker status was available in 16 (53%) MILC; 12 were oestrogen receptor+/progesterone receptor+/human epidermal growth factor receptor 2- (ER+/PR+/HER2-), two were ER+/PR-/HER2-, one was ER-/PR-/HER2+ and one was ER-/PR-/HER2 2+ but insufficient for fluorescence in-situ hybridisation (FISH) analysis. Median follow-up was 49 months. A patient with MILC at the excision margin of the index excision specimen did not undergo re-excision; 15 months later she developed an ipsilateral invasive carcinoma with ductal and lobular features and died of disease 73 months after initial diagnosis. All other 29 patients are alive with no evidence of disease.
MILC is a relatively indolent tumour arising in classic and variant LCIS, with a low risk of axillary or distant metastases.
微浸润性小叶癌(MILC)是一种罕见的微浸润性癌,其病理和临床特征尚不完整。我们试图确定2009年至2023年在我们机构诊断出的MILC的临床和病理特征。
收集患者的人口统计学、病理和临床数据。排除有浸润性癌既往史或同步病史的患者。研究队列包括30名女性患者,中位年龄为53岁。最常见的影像学表现为微钙化(63%)。3例(10%)仅通过活检诊断为MILC,22例(73%)仅通过切除诊断,5例(17%)通过活检和切除均诊断为MILC。大多数MILC为单灶性(57%)。90%的MILC病例与经典型小叶原位癌(LCIS)相关,27%与旺炽型LCIS相关,17%与多形性LCIS相关。21例行前哨淋巴结活检的患者中无一例有淋巴结转移。16例(53%)MILC患者有生物标志物状态信息;12例为雌激素受体阳性/孕激素受体阳性/人表皮生长因子受体2阴性(ER+/PR+/HER2-),2例为ER+/PR-/HER2-,1例为ER-/PR-/HER2+,1例为ER-/PR-/HER2 2+但荧光原位杂交(FISH)分析不足。中位随访时间为49个月。一名在索引切除标本切缘处有MILC的患者未进行再次切除;15个月后,她发生了具有导管和小叶特征的同侧浸润性癌,并在初次诊断后73个月死于疾病。其他29例患者均存活,无疾病证据。
MILC是一种起源于经典型和变异型LCIS的相对惰性肿瘤,腋窝或远处转移风险较低。